Answers are grounded in this paper and cite their sources.
Identifies REXO4's role in reducing genome instability in tumors, suggesting a method for enhancing antitumor immunity.
R-loop metabolism is closely associated with genome stability and tumors. Here, we identify an exonuclease REXO4, which collaborates with RNaseH1 endonuclease to degrade R-loops in an “endo/exo-cleavage coupling” manner. Specifically, REXO4 directly degrades the RNA strand in R-loops from the end or internal nick through its 3′-5′ exonuclease activity and stimulates RNaseH1 endonuclease activity. The genome-wide R-loop regions regulated by REXO4 highly overlap with those regulated by RNaseH1, and REXO4 overexpression counteracts genome-wide R-loop accumulation caused by RNaseH1 deficiency. Furthermore, REXO4-deficient tumors display elevated R-loop mutation burden, and tumor patient-derived mutations in REXO4 enzymatic region all impair R-loop cleavage activity. Besides, we identify a compound 17 (named REXO4-IN-17) capable of inhibiting REXO4 nuclease activity. Interfering with REXO4 increases the sensitivity of tumor cells to alkylating and G4 stabilizing chemotherapeutic drugs and activates cGAS-mediated antitumor immunity. Therefore, our study proposes an endo/exo-cleavage coupling the R-loop processing model, which provides additional insights into the link between R-loop–associated genome instability, antitumor immunity, and tumors.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: